Plasmodium brasilianum is a species of malaria-causing parasite in the genus Plasmodium. It is the causative agent of Brazilian malaria and is one of the most common species of malaria-causing parasite in the Americas. This species of parasite is transmitted between humans by the bite of an infected female Anopheles mosquito. Symptoms of infection include fever, headache, and chills and can range in severity from mild to life-threatening. Treatment for malaria caused by Plasmodium brasilianum includes antimalarial medications such as chloroquine and artemether-lumefantrine.

Circumsporozoite Protein (CS) is a protein that is produced by the Plasmodium Brasilianum parasite during the sporozoite stage of its life cycle. This protein is essential for the invasion of the parasite into the host’s liver cells, where it can multiply and cause further damage.

Recent studies have shown that there is a significant link between Plasmodium Brasilianum and Circumsporozoite Protein (CS). Specifically, researchers have found that the CS protein produced by Plasmodium Brasilianum is highly similar to the CS protein produced by Plasmodium vivax, which is responsible for causing malaria in humans.

This similarity is important because it suggests that Plasmodium Brasilianum may be capable of infecting humans in a similar way to Plasmodium vivax. This could have important implications for the diagnosis and treatment of malaria in areas where both parasites are present.

The application of Plasmodium brasilianum cDNA and recombinant antigens is mainly used for the diagnosis and management of diseases caused by this parasite. These antigens can be used to identify the presence of the parasite in the bloodstream and to assess the severity of the infection. They can also be used to detect the presence of antibodies specific to the parasite in the blood, which can help to determine the effectiveness of treatments. The recombinant antigens can also be used to develop vaccines against the parasite, as well as for the development of diagnostic tools that can detect the presence of the parasite in the body.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.